WO2025133694 - FCRN/HSA-BINDING MOLECULES AND METHODS OF USE
National phase entry is expected:
Publication Number
WO/2025/133694
Publication Date
26.06.2025
International Application No.
PCT/IB2024/000718
International Filing Date
20.12.2024
Title **
[English]
FCRN/HSA-BINDING MOLECULES AND METHODS OF USE
[French]
MOLÉCULES DE LIAISON À FCRN/HSA ET PROCÉDÉS D'UTILISATION
Applicants **
ARGENX BV
Inventors
BOBKOV, Vladimir
SILENCE, Karen
VAN SANTBERGEN, Jolien
BIGIRIMANA, René
DE HAARD, Johannes
BLANCHETOT, Christophe
Priority Data
63/612,866
20.12.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4499 | |
| EPO | Filing, Examination, Granting | 62820 | |
| Japan | Filing, Examination, Granting | 4066 | |
| South Korea | Filing, Examination, Granting | 5950 | |
| USA | Filing, Examination, Granting | 20790 |
Total:
98,125
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Provided herein are binding molecules comprising a human neonatal Fc receptor (FcRn) binding molecule and at least one HSA-binding domain linked to the FcRn-binding molecule. Polynucleotides, vectors, host cells, and methods of production are also provided herein. Methods of treating an antibody-mediated disorder with an FcRn/HSA-binding molecule are further provided.[French]
L'invention concerne des molécules de liaison comprenant une molécule de liaison au récepteur Fc néonatal humain (FcRn) et au moins un domaine de liaison HSA lié à la molécule de liaison au FcRn. L'invention concerne également des polynucléotides, des vecteurs, des cellules hôtes et des procédés de production. L'invention concerne en outre des méthodes de traitement d'un trouble médié par anticorps avec une molécule de liaison à FcRn/HSA.